Zamira Lifesciences India Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 1.39 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
- Revenue Growth 17.66%
- Profit Growth -146.43%
- Ebitda -113.36%
- Net Worth -4.20%
- Total Assets 24.21%
About Zamira Lifesciences India
Zamira Lifesciences India Private Limited (ZLIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 05 July 2014 and has a history of Ten years and six months. Its registered office is in Faridabad, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.39 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shaveta Sood, Ravindra Dingorkar, and Stewart Cairns serve as directors at the Company.
Company Details
-
Location
Faridabad, Haryana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U01220HR2014PTC052661
-
Company No.
052661
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Jul 2014
-
Date of AGM
27 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Zamira Lifesciences India?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Stewart Cairns
|
Additional Director | 15-Nov-2021 | Current |
Shaveta Sood
|
Director | 14-Jul-2023 | Current |
|
Ravindra Dingorkar
|
Director | 30-Jun-2022 | Current |
Financial Performance of Zamira Lifesciences India.
Zamira Lifesciences India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 17.66% increase. The company also saw a substantial fall in profitability, with a 146.43% decrease in profit. The company's net worth dipped by a decrease of 4.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zamira Lifesciences India?
In 2023, Zamira Lifesciences India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹5.00 M
Charges Breakdown by Lending Institutions
- Others : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Mar 2019 | Others | ₹5.00 M | Satisfied |
How Many Employees Work at Zamira Lifesciences India?
Unlock and access historical data on people associated with Zamira Lifesciences India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zamira Lifesciences India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zamira Lifesciences India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
